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Abstract Axonal demyelination is a consistent pathological
sequel to chronic brain and spinal cord injuries and disorders
that slows or disrupts impulse conduction, causing further
functional loss. Since oligodendroglial progenitors are
present in the demyelinated areas, failure of remyelination
may be due to lack of sufficient proliferation and differen-
tiation of oligodendroglial progenitors. Guanosine stimu-
lates proliferation and differentiation of many types of cells
in vitro and exerts neuroprotective effects in the central
nervous system (CNS). Five weeks after chronic traumatic
spinal cord injury (SCI), when there is no ongoing recovery
of function, intraperitoneal administration of guanosine
daily for 2 weeks enhanced functional improvement
correlated with the increase in myelination in the injured
cord. Emphasis was placed on analysis of oligodendrocytes
and NG2-positive (NG2+) cells, an endogenous cell
population that may be involved in oligodendrocyte
replacement. There was an increase in cell proliferation
(measured by bromodeoxyuridine staining) that was attrib-
utable to an intensification in progenitor cells (NG2+ cells)
associated with an increase in mature oligodendrocytes
(determined by Rip+ staining). The numbers of astroglia
increased at all test times after administration of guanosine
whereas microglia only increased in the later stages
(14 days). Injected guanosine and its breakdown product
guanine accumulated in the spinal cords; there was more
guanine than guanosine detected. We conclude that func-
tional improvement and remyelination after systemic admin-
istration of guanosine is due to the effect of guanosine/
guanine on the proliferation of adult progenitor cells and
their maturation into myelin-forming cells. This raises the
possibility that administration of guanosine may be useful in
the treatment of spinal cord injury or demyelinating diseases
such as multiple sclerosis where quiescent oligodendroglial
progenitors exist in demyelinated plaques.
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Abbreviations
BBB Basso-Beattie-Bresnahan locomotor rating
scale
bFGF basic fibroblast growth factor
BrdU bromodeoxyuridine
CE capillary electrophoresis
CNS central nervous system
DAB diaminobenzidine
FITC fluorescein isothiocyanate
GFAP glial fibrillary acidic protein
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TdT terminal deoxynucleotidyltransferase
TGF beta transforming growth factor beta
TUNEL terminal deoxynucleotide transferase dUTP
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Introduction
Demyelination contributes to functional deficits in central
nervous system (CNS) disorders [1–3]. Traumatic spinal cord
injury (SCI) induces local inflammation and demyelination
in the white matter around the lesion resulting in disrupted
axonal conduction [4–7]. Remyelination is critical for
recovery, but does not occur spontaneously [8–11]. Spinal
cords contain endogenous progenitors that can proliferate
and differentiate into mature oligodendroglia and remyelinate
axons under certain circumstances [12–14]. After acute SCI
in rats, oligodendrocyte precursors proliferate in the first
2 weeks but are “silent” thereafter [15], possibly because the
oligodendroglial precursors cannot differentiate into mature
oligodendroglia capable of remyelinating axons. Enhance-
ment of proliferation of oligodendrocytes or progenitors may
lead to repair and restoration of function after SCI.
Neurotrophic factors restore physiological function by
promoting oligodendrocyte proliferation and axonal sprouting
[16–19], regulating the proliferation of oligodendrocyte
progenitors [3] and modulating the differentiation [20–22]
and the maturation of oligodendrocyte precursors into
myelin-forming cells [23, 24].
Guanosine has trophic effects on many cell types [25–
28], and we have some evidence that guanine acts similarly.
For example, it stimulates proliferation of a variety of cells
in culture [25, 28] and promotes synthesis and release of
several potentially neuroprotective trophic factors from a
variety of cells, including neuron growth factor (NGF) from
astrocytes as well as basic fibroblast growth factor (bFGF)
and transforming growth factor beta (TGF beta) [25, 27].
Extracellular guanosine itself also enhances outgrowth of
nerve processes from PC12 cells and from primary cultures
of embryonic rat brain neurons [25]. As well, it acts
synergistically with NGF to promote outgrowth of neurites
[29, 30].
Our preliminary data [31] showed that 35 days after
moderate traumatic injury of the spinal cord of rats, when
the initial spontaneous incomplete recovery of function had
plateaued, systemic administration of guanosine (intra-
peritoneally 8 mg/kg body weight) for 7 days enhanced
locomotor functional recovery that continued to improve
throughout the 7-day duration of the treatment and
correlated with the increase in myelination. In the present
study, we treated rats for up to 14 days to determine
whether guanosine-induced functional improvement was
due to triggering the endogenous adult progenitors. Mean-
while, we also examined the uptake and tissue distribution
of systemically administered guanosine.
Materials and methods
All experiments were performed in compliance with the
requirements of the Animals for Research Act of Ontario,
Canada and the Guidelines of the Canadian Council on
Animal Care, and had been approved by the Animal
Research Ethics Board of McMaster University.
Spinal cord injury Adult female Wistar rats (280–300 g
weight, Charles River) were anaesthetized with isoflurane
(3–5%): O2 (1 l/min). Buprenorphine (0.03 mg/kg body
weight, subcutaneously) was administered prior to surgery
for pain relief. Moderate spinal cord injury was induced by
crushing exposed cords with modified coverslip forceps
[31–33]. The forceps were closed slowly over 2 s and the
compression sustained for 15 s. The muscles and fat pad
over the lesion were sutured and the skin was closed with
stainless steel clips. Post-operatively, the rats were kept
quiet and warm [31, 34, 35].
Behavioural assessment and drug administration Rats
were handled daily for 2 weeks pre-operatively to
acclimatize them to the experimental procedures and
behavioural test. After the spinal injury, locomotor
recovery was assessed weekly for 35 days in an open
field walking task (OFWT) before treatment. Cagemates
(two animals) were placed in the centre of the open field,
formed by a child’s circular plastic swimming pool (1.3 m
in diameter). They were observed for 5-min periods and
scored for general locomotor ability using the Basso-
Beattie-Bresnahan (BBB) locomotor rating scale [36, 37].
Rats were rated on a scale of 0 to 21, with 0 being no
function and 21 being normal. If the animal stopped
moving for a minute, it was placed again in the centre of
the open field; otherwise it was left alone for the duration of
the 5-min test period.
On day 35 following the injury, rats were randomly
assigned to three groups. One group of rats was used for
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baseline behavioural and histological analysis. The other
rats received either daily intraperitoneal (i.p.) injections of
8 mg/kg guanosine or the same volume of saline containing
0.001 N NaOH [31] for 2 weeks. The open field walking
testing was performed once a day from days 35 to 48 post-
surgery (0 to 14 days post-treatment). Groups of 9–12 rats
were killed by perfusion/fixation for immunohistochemical
analysis at 1, 3, 7 or 14 days after treatment.
BrdU administration Bromodeoxyuridine (BrdU) was used
to label proliferating cells after treatment. BrdU (50 mg/kg
in sterile saline; Sigma, B-5002) was injected intraperito-
neally daily for 1, 3, 7 or 14 consecutive days, beginning
the day treatment was initiated, thereby reflecting cell
proliferation over the entire treatment period.
Tissue processing and immunohistochemistry On post-
operative days 35, 36, 38, 42 or 49 (representing baseline,
1, 3, 7 or 14 days treatment), rats were deeply anaesthetized
with sodium pentobarbital (50–60 mg/kg body weight, i.p.)
immediately following the final locomotor testing and
perfused transcardially with 100 ml 0.1 M phosphate-
buffered saline (PBS) containing 0.1% heparin, followed by
300–500 ml of 4% paraformaldehyde (PFA). T9 to L1
segments of the spinal cords were removed and incubated
in the same fixative for 2 h at room temperature and then
cryoprotected in 30% sucrose PBS solution. A segment of
each cord, extending from 5 mm rostral to 5 mm caudal
to the lesion site was embedded in medium (Tissue-Tek®
O.C.T. compound, Sakura Finetek USA, Inc., Torrance,
CA, USA). Serial transverse sections were cut at 15- to
20-μm intervals on a cryostat and mounted onto slides
(ColorFrost/Plus; Fisher, Pittsburgh, PA, USA). Every
fifth section was stained with the lipophilic dye Luxol
fast blue to stain myelin [38]. Adjacent sections were
stained immunohistochemically with the various antibodies
described below.
For BrdU immunohistochemistry, 6% hydrogen peroxide
was used to reduce endogenous peroxidase activity,
followed by three 10-min PBS rinses and incubation in
1 N HCl at 37°C for 30 min. After rinsing, a blocking
solution [5% bovine serum albumin (BSA) in 0.1% Triton-
100] was applied for 1 h; sections were subsequently
incubated in rat anti-BrdU (1:200 in 1% BSA in 0.1%
Triton-100; Serotec, Raleigh, NC, USA) at 4°C overnight
in a humid chamber. Sections were then rinsed and
incubated with biotinylated horse anti-rat IgG secondary
antibodies. Sections were then incubated with Elite ABC
(Vector Laboratories, Burlingame, CA, USA) for 1 h,
followed by 3,3′-diaminobenzidine (DAB) substrate kit for
peroxidase (Vector Laboratories, Burlingame, CA, USA)
for 5–10 min. Sections were dehydrated, coverslipped and
examined under a microscope.
To determine the fate of newly born cells after SCI,
double-fluorescent immunolabelling was performed, com-
bining BrdU with one of the cell-specific phenotypic
markers listed below. For double immunofluorescence,
sections were pretreated with HCl as described above and
incubated with BrdU antibody mixed with one of the
following antibodies in PBS at 4°C overnight in a humid
chamber: rabbit anti-MBP (myelin basic protein) polyclonal
antibodies (1:50; Chemicon Int., Temecula, CA, USA),
rabbit anti-NG2 polyclonal antibodies (chondroitin sulfate
proteoglycan for oligodendroglial progenitors; 1:200;
Chemicon Int. Temecula, CA, USA), mouse anti-Rip
monoclonal antibodies (mature oligodendrocyte-specific
marker: Reactive Immunology Protein; 1:200; Chemicon
Int., Temecula, CA, USA; [39]), rabbit anti-glial fibrillary
acidic protein (GFAP) polyclonal antibodies (1:600;
Zymed® Lab-SA System Kit, San Francisco, CA, USA)
and mouse anti-microglial-specific marker OX-42 mono-
clonal antibodies (1:200; CD11b, Research Diagnostics
Inc., Flanders, NJ, USA). For Rip and OX-42 monoclonal
antibodies single staining, sections were developed with
fluorescein isothiocyanate (FITC)-conjugated goat anti-
mouse IgG. For BrdU and polyclonal antibodies (NG2 or
MBP or GFAP) double immunolabelling, sections were
developed using a mixture of FITC-conjugated goat anti-rat
IgG and rhodamine-conjugated goat anti-rabbit IgG in 1%
normal goat serum and 0.25% Triton X-100; 1:200
(Invitrogen, Carlsbad, CA, USA) for 2 h. To examine the
contribution of Schwann cells from the peripheral nervous
system (PNS) in the remyelination process, sections were
immunolabelled with specific markers for Schwann cell
myelin P0 (a rabbit polyclonal anti-P0 antibody was kindly
donated by Prof. Marie T. Filbin, Department of Biology,
CUNY, NY, USA; 1:200) and secondary antibody using
rhodamine-conjugated goat anti-rabbit IgG. For detection of
apoptotic cells, a terminal deoxynucleotidyltransferase
(TdT)-mediated dUTP nick end labelling (TUNEL) stain
was performed using the ‘In situ Cell Death Detection Kit,
Fluorescein’ (Roche Molecular Biochemicals, Mannheim,
Germany), according to the manufacturer’s instructions.
Quantification To quantify the amount of myelin present at
the injury site before and after treatment, the Luxol fast blue-
stained section from each cord (n=7–10 for each group) that
contained the greatest lesion area was selected together with
the adjacent two caudal and two rostral Luxol blue-stained
sections. Luxol fast blue staining was also done on cords of
five additional unoperated normal animals for comparative
purposes. Digital photographs were taken of the sections.
The total area of each section and the area of the fast blue-
stained portion were measured using a computerised
Bioquant BQ-TCW98 image analysis program by an
investigator who was blind to group assignment.
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Fig. 1 Systemic treatment with guanosine improves locomotor
function and correlates with increased myelination in rats with stable
chronic spinal cord injury. a After spinal cord crush, locomotor
function was assessed in an open field walking task (OFWT) and
scored using a standard scale (“Materials and methods”). No further
improvement in locomotor performance occurred after 28 days. b On
days 35–48 after injury (days 1 to 14 of treatment in the figure; the
first test done immediately prior to the first treatment), animals were
randomly divided into two groups. One group received guanosine (▴),
the other group received vehicle (♦). The locomotor function in the
control group did not change significantly throughout the 14 days of
vehicle administration. In contrast, rats that received guanosine
showed a marked improvement in locomotor behaviour, which was
significantly ( p<0.05) better than vehicle-treated control animals from
the 5th day of treatment onward. c, d Luxol fast blue staining of cross
sections of spinal cords from guanosine- (d) and vehicle- (c) treated
animals at the lesion site 48 days after the initial lesion (after 14 days
treatment) shows increased Luxol fast blue-stained material in d
compared to the vehicle-treated control group in c. DC dorsal column
at the lesion. Scale bar=50 μm. e The total area of each section and of
the Luxol fast blue-stained portion were measured following the
protocol in “Materials and methods”. The quantitative results show
that the cords from guanosine-treated animals had significantly greater
myelinated area (*p<0.05), as estimated from the Luxol fast blue
staining, than cords from vehicle-treated control animals, which in turn
had significantly less myelinated area (**p<0.001) than unoperated
animals. f Correlation between behavioural and histological outcomes
was analysed using regression analysis. The data show that the Luxol
fast blue-stained area in the injured cords from animals treated with
guanosine correlated with their behavioural recovery in open field
walking scores, correlation coefficient of 0.72, indicating that the
recovery of function may be related to the increase in myelin. Myelin
immunofluorescent staining of cross sections of spinal cords from
vehicle- (g) and guanosine- (h) treated animals at the lesion site
14 days after treatment shows that guanosine-treated cords (h)
contained more myelin basic protein (MBP)-positive profiles from
central nervous system at the injured site compared to the vehicle-
treated control group (g). IS injured site. Whereas, in i (vehicle-treated
cord) and j (guanosine-treated cord) immunolabelling with specific
markers for Schwann cell myelin P0 indicated that Schwann cells from
the peripheral nervous system did not contribute to guanosine-induced
remyelination. Scale bar=50 μm for all
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For quantification of cell proliferation, five to seven
sections taken from the penumbra of the lesion and spaced
about 100 μm apart were analysed for each animal (n=7–9
animals per group). Cellular proliferation was determined
by counting the total number of BrdU+ nuclei in spinal
cord cross sections. Low power sections were digitized and
manually outlined using an image analysis system. Any
cavities present in the sections were excluded from
analysis. Positively labelled nuclei were counted automat-
ically. The threshold was set such that only positively
labelled profiles of the appropriate size were counted. Data
are expressed as cells per section.
The total number of NG2+ progenitor cells and the
number of those that proliferated (double-labelled for NG2
and BrdU: NG2+/BrdU+) was determined by manual
counting. Cell counting was done conservatively, and a
positive profile was counted as a cell only when clearly
defined borders could be detected completely around and
adjacent to the entire nucleus. Data are expressed as the
number of immunostained cells per section.
Mature oligodendrocytes in injured cords were identified
with Rip, a specific marker for mature oligodendrocytes
that recognises an unknown epitope [39] and has been used
successfully in the CNS to label both oligodendrocyte
processes and myelin sheaths. The number of mature
oligodendrocyte (Rip+ cells) in the tissue sections was
determined by manual counting.
Evaluation of exogenous guanosine distribution A guano-
sine solution (8 mg/kg) was administered intraperitoneally
to rats with spinal cord injury induced 5 weeks previously.
Samples of spinal cord were taken from the site of the
lesion and immediately above or below the lesion just
before the intraperitoneal injection of guanosine and at 7.5,
30 and 60 min after the guanosine injection. There were
between three and six animals at each time point. Samples
of spinal cord were placed in 0.5 ml of cold 0.4 M
perchloric acid solution and immediately homogenized.
Samples were then centrifuged (4°C, 10,000 g, 10 min) to
remove proteins precipitated by perchloric acid and the
supernates containing the soluble molecules were neutral-
ized with KOH solution and centrifuged (4°C, 10,000 g,
5 min). Samples were filtered with 0.2-μm filters (Milli-
pore, Billerica, MA, USA) and stored at −70°C before
high-performance liquid chromatography (HPLC) [40] or
capillary electrophoresis (CE) analysis.
Tissue concentrations of guanosine and guanine To eval-
uate the concentration of guanosine and its principal
degradation product, guanine, in spinal cords before and
after the intraperitoneal injection of guanosine, either
HPLC or CE was used. There was no significant
difference in the values obtained by these two methods
so the data represent the mean of values obtained by both
analyses. HPLC analysis was carried out using an Agilent
1100 series HPLC (Agilent Technologies, Waldbronn,
Germany) and an ion-pair technique. Separation was
carried out with a reverse-phase analytical column
(LiChroCART 125-4 LiChrospher 100 RP-18 5 μm,
Merck, Darmstadt, Germany) and the flow rate was
1.5 ml/min. A 15-min linear gradient was applied from
100% buffer A (60 mM KH2PO4 and 5 mM tetrabutyl-
ammonium phosphate, pH 6) to 100% buffer B (30%
methanol plus 70% buffer A). CE separations were carried
out using an HP3DCE capillary electrophoresis system
(Agilent Technologies, Waldbronn, Germany) equipped
with a diode array detection system. Analysis was
performed using a 80.5 cm × 50 μm ID × 375 μm OD
uncoated fused silica capillary from Agilent Technologies
(Waldbronn, Germany) with an effective length of 72 cm to
the detector window. The capillary temperature was kept
constant at 37°C and the running buffer was 10 mM borate,
pH 9.3. The samples were injected by pressure (50 mb for
40 s) and the separation was conducted at 22 kV. Detection
took place at 254 nm and purines were identified by their
migration times and UV spectra using the diode array
detector (Agilent Technologies, Waldbronn, Germany).
Statistical analysis Data are expressed as mean±SEM.
Behavioural scores were analysed by the Kruskal-Wallis
non-parametric analysis of variance (ANOVA). Post hoc
comparisons were made using the Dunnett’s test. Correla-
tion between behavioural and histological outcomes was
analysed using regression analysis. Significance was set at
p<0.05.
Fig. 1 (continued)
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Results and discussion
After SCI, motor function in the legs partially recovered
over 3–4 weeks, after which there was no further
improvement (Fig. 1a). Daily guanosine for 14 days
(8 mg/kg intraperitoneally beginning 35 days after injury)
produced improvement in locomotor performance over the
next 2 weeks; control rats showed no improvement
(Fig. 1b). This treatment regimen was associated with
significantly increased amounts of myelin in the penumbra
of the cord lesions shown by Luxol fast blue staining
(Fig. 1c–e). The extent of Luxol fast blue staining in the
Fig. 2 Quantitative assessment of immunostaining shows that
systemic treatment with guanosine stimulates endogenous oligoden-
droglial progenitors (NG2+ cells) to proliferate and mature in rats with
stable chronic spinal cord injury. a, b Bromodeoxyuridine (BrdU) was
used to label proliferating cells after treatment. BrdU immunostaining
in cross sections from vehicle- (a) and guanosine- (b) treated animals
at the lesion 14 days after treatment shows increased BrdU+ nuclei in
b compared to the vehicle-treated control group in a. Scale bar=
50 μm. c Quantitative analysis shows that 7 or 14 days after guanosine
treatment there was a significant increase in the number of BrdU+
cells compared with vehicle-treated controls. d, e Demonstrate
examples of double-fluorescent immunostaining using antibodies
against BrdU (in green) and a marker (NG2) for oligodendroglial
progenitors (in red) in cross sections from vehicle- (d) and guanosine-
(e) treated animals at the lesion 14 days after treatment. Scale bar=
50 μm. f–h Show quantification of proliferating progenitors (NG2+/
BrdU+ double-labelled cells; f) and total number of NG2 cells (g).
Data indicate that after 7 or 14 days administration guanosine
significantly stimulates proliferation of oligodendroglial progenitors
(f, g). Concurrently, guanosine also significantly increases the number
of mature oligodendroglia shown in i and j compared to vehicle-
treated controls (h, j) using fluorescent immunostaining with a specific
marker (Rip) to label the mature oligodendroglia. Scale bar=50 μm
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injured cords correlated with each animal’s open field
walking scores (r=0.72; p<0.05; Fig. 1f), indicating that
guanosine-induced functional recovery may be related to
the increase in myelin. Immunostaining for CNS myelin
basic protein (MBP; Fig. 1g,h) and a specific marker for
Schwann cell myelin, P0 (Fig. 1i,j) showed that Schwann
cells from the peripheral nervous system did not enter
spinal cord and, therefore, did not contribute to the
remyelination.
To determine whether existing cells elaborated the
myelin or whether it was a product of other cells that
proliferated and subsequently elaborated myelin, the
number of proliferating cells was determined by counting
all BrdU+ nuclei in cross sections of the lesion pen-
umbra at different times after treatment. In the first
3 days after treatment, cell proliferation at the injury site
in both guanosine-treated and control animals was not
different from baseline (immediately before treatment;
Fig. 2c), although at 3 days there was a trend toward more
BrdU+ cells in guanosine-treated animals than controls
(112±25 vs 79±16). At 7 and 14 days after guanosine
treatment, the number of BrdU+ cells increased signifi-
cantly; there were 382±42 BrdU+ cells per section at
7 days and 477±49 at 14 days compared with only 88±20
at 7 days and 95±22 at 14 days in controls ( p<0.05;
Fig. 2a–c). There were few dividing cells beyond the
lesion margins.
Oligodendrocytes that survive the demyelinating insult
are not thought to be able to contribute to remyelination
[41, 42]. Instead, endogenous oligodendrocyte progenitor
cells local to the lesion are believed to be the source of new
myelinating cells [43]. Previous studies have illustrated that
NG2+ cells are the major cycling cell within the resting
adult CNS [14, 44] and express many characteristics of
oligodendroglial lineage cells, not least their ability to
differentiate into oligodendrocytes when isolated into
culture. Their role in demyelination and remyelination has
been extensively studied and there is evidence that they are
the cells responsible for myelin repair [43, 45–48]. To
determine whether the proliferating cells were related to
NG2+ oligodendroglial progenitor cells, we counted the
total number of NG2+ progenitor cells and the number that
had proliferated (NG2+/BrdU+) from 2 mm rostral to 2 mm
caudal to the lesion site (Fig. 2d,e). There was minimal
turnover in the NG2+ cells in the spinal cord during the
first 3 days in both guanosine-treated and control animals
(13±5 in the guanosine group vs 9±4 cells per section in
controls; Fig. 2f). By 7 days, guanosine significantly
stimulated progenitor proliferation (85±18 vs 13±4
NG2+/BrdU+ cells/section; Fig. 2f); these cells were
observed throughout the penumbra with the majority
localised in the dorsal columns. Enhanced proliferation of
the NG2+ progenitors after guanosine persisted, and by
14 days, double-labelled progenitors in the guanosine-
treated group were eightfold more than in controls (108±
12 vs 13±5 NG2+/BrdU+ cells/section; Fig. 2f).
The total number of NG2+ cells was also determined.
During the first 3 days, there was no significant difference
in the numbers of NG2+ cells in cords at baseline after
vehicle treatment or guanosine treatment (Fig. 2g). By
7 days, guanosine treatment increased the total NG2+ cells
from 96±22 cells/section at baseline to 266±38 cells/
section—more than 2 times higher than in the control group
(110±24 /section; Fig. 2g). By 14 days, the numbers of
double-labelled progenitors in the cords of guanosine-
treated animals were threefold higher than controls (347±
36 NG2+ cells/section for guanosine-treated animals; 115±
24 cells/section for controls; Fig. 2g).
Mature oligodendrocytes were identified with Rip+
staining (Fig. 2h,i). Guanosine had no effect on mature
oligodendroglia 3 days after treatment; at 7 and 14 days,
there was a significant increase in Rip+ cells in the
penumbra of the cords of animals that had received
guanosine compared to controls (7 days: 468±40 vs 205±
25; and at 14 days: 492±43 vs 219±23 per section, p<
0.01; Fig. 2j).
Guanosine treatment stimulated astrocyte proliferation in
the penumbra as early as 3 days and throughout the 14 days
of treatment (Fig. 3a,b) and was detected by antibodies to
glial fibrillary acidic protein (GFAP). Astrocytes may
stimulate oligodendroglial progenitor proliferation or in-
duce their migration [49]. Guanosine did not alter the
Fig. 2 (continued)
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numbers of OX-42+ microglia/macrophages until 14 days
after treatment. At day 14, guanosine significantly in-
creased OX-42+ cells compared to vehicle treatment
(Fig. 3c–e; p<0.05).
Guanosine inhibits apoptosis due to a number of stimuli
[50–52]. After stroke and spinal cord injury, intrinsic stem
cells and progenitors proliferate and differentiate but many
die through apoptosis [15, 53–55]. In these experiments,
guanosine did not prevent cell death (measured by TUNEL)
(Fig. 4), indicating that the protective effects of guanosine
do not result from a reduction in precursor cell apoptosis.
Before the intraperitoneal injection of guanosine, there
were detectable amounts of guanosine and its metabolic
product guanine in the spinal cords of injured rats (time 0,
Fig. 5a,b). There were no significant differences in
guanosine or guanine in the samples of the spinal cords
above, at or below the lesion. After guanosine injection, the
amount of both guanosine and guanine increased, reaching
a maximum by 30 min; the amounts of guanosine and
guanine were about twofold and fivefold higher than those
detected before the injection (Fig. 5a,b). As with the basal
levels (time 0), there was no difference in the amounts of
guanosine above, at or below the lesion. Interestingly,
guanine levels were always higher than those of guanosine
at each of the times tested after injection (Fig. 5a,b).
New oligodendrocytes in injured spinal cords come from
a population of endogenous progenitor cells present in the
CNS that can differentiate into mature cells capable of
myelinating axons [3, 12, 13, 56]. The data from the present
study showed that the increase in the number of NG2+ cells
is associated with an increase in Rip+ cells. Our data
indicated that guanosine treatment induced an increase of
mature oligodendroglia (Rip+ cells), likely due to prolifer-
ation and differentiation of their progenitor (NG2+) cells.
Therefore, one would expect that Rip+ cells increase after
NG2+ cells. However, this was not observed. But guanosine
may well stimulate the proliferation of oligodendroglial
Fig. 4 Guanosine treatment did not affect apoptosis in the cords with
chronic, stable spinal cord injury. For detection of apoptotic cells, a
terminal deoxynucleotidyltransferase (TdT)-mediated dUTP nick end
labelling (TUNEL) stain was performed using the ‘In situ Cell Death
Detection Kit, Fluorescein’. No obvious difference in number of
TUNEL-positive cells was observed between vehicle- (a) or guano-
sine- (b) treated spinal cord sections. Scale bar=50 μm for all
Fig. 3 Cross sections of the cords at the injury site staining with GFAP
and OX-42 from guanosine-treated and vehicle-treated rats 14 days
after treatment following chronic spinal cord injury. a, b Demonstrate
examples of GFAP-positive astrocytes (in red) in cross sections from
vehicle- (a) and guanosine- (b) treated animals at the injury site
14 days after treatment. c, d Show OX-42-immunofluorescent staining
of cross sections of spinal cords from vehicle- (c) and guanosine- (d)
treated animals at the lesion site 14 days after treatment. Quantifica-
tion showed more OX-42-immunolabelled cells in cords of guanosine-
treated rats (d, e) compared to cords of vehicle-treated rats (c, e; p<
0.05). Scale bar=50 μm for all
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progenitor cells at several stages of development. This would
account for the observed results. Additionally, we cannot
exclude that other possible mechanisms are involved in the
process; for example, mature oligodendroglia could migrate
from the adjacent normal tissue to the injury site soon after
guanosine treatment.
Whether the effects on remyelination are due to
guanosine, guanine or both is not clear. However, since
a putative receptor for guanosine has been identified in the
CNS, and since PNP (purine nucleoside phosphorylase) in
CNS permits the interconversion of guanine and guano-
sine enabling guanine to act as a reservoir for guanosine,
it is possible that guanosine may be responsible for
causing the proliferation of the endogenous progenitor
cells and the subsequent remyelination process, although
this is by no means certain. But, since guanine itself is
difficult to administer because of its poor solubility,
administration of guanosine is the most effective delivery
mechanism.
The mechanism by which remyelination is facilitated
after chronic, traumatic SCI is unknown. Guanosine has
been shown to stimulate the production and/or release of a
variety of trophic factors [25]; for example bFGF, NGF and
NT-3 have been demonstrated to increase the proliferation
and survival of oligodendrocyte progenitors [3, 16, 57],
induce oligodendroglial genesis [58–61], stimulate the
proliferation of oligodendrocyte precursors and enhance
remyelination after spinal cord traumatic injury [18, 19] and
after toxin-induced demyelination [62]. There are no
published reports of the effects of guanine in the vivo
systems. However, in cultured cells, guanosine stimulates
cell division apparently through a pertussis toxin-sensitive
process involving MAP kinase [63]. Moreover, there is
evidence of a G protein-coupled receptor in brain mem-
branes that might be a candidate for a guanosine receptor
[64]. Further studies will permit us to distinguish amongst
these possibilities.
The present findings are the first to show that systemic
treatment with guanosine after chronic SCI induces an
improvement in function that is accompanied by the
formation of mature oligodendrocytes. This effect of
guanosine/guanine may be attributable to direct or indirect
stimulation of endogenous oligodendrocyte lineage progen-
itors in the spinal cord and remyelination of axons at the
injury site.
These findings raise the possibility that the administra-
tion of guanosine may be effective in treating spinal cord
injuries and in the treatment of demyelinating diseases such
as multiple sclerosis where quiescent progenitors exist in
demyelinated plaques [65–70].
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Fig. 5 Guanosine (a) and guanine (b) in spinal cord samples of rats
with chronic spinal cord injury before and after intraperitoneal
injection of guanosine. Guanosine (8 mg/kg) was administered
intraperitoneally to rats 5 weeks after the spinal cord injury. Before
or at the indicated time points after the injection, samples of spinal
cord from 3–6 animals were taken from the site of the lesion and
immediately above and below the lesion. The tissue content of
guanosine and its metabolic product guanine was measured by HPLC
and CE analysis. Data are the mean±SEM
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